Correct, I was asleep! But I did watch the MOA discussion from the ODAC meeting this morning. The MSB response reiterated that they clearly believe this therapy is not just a treatment for SR-aGVHD, but a treatment for a wide range of diseases involving systemic inflammation.
My point is that whether the MOA is, in fact, generalisable to other clinical applications beyond SR-aGVHD will have to be borne out in further clinical trials involving the treatment of other diseases. MSB have me convinced, and I desperately hope the results of future clinical trials for other applications (incl. for C-19-related ARDS) continue to support the theorised MOA!
Correct, I was asleep! But I did watch the MOA discussion from...
-
- There are more pages in this discussion • 12,512 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |